The expression of MMP2 is a prognostic marker for patients with MM that could independently predict patient survival (55), and its expression has been related to the poorer survival of patients with melanoma (55), consistent with varied PCDH9 expression in melanoma cells. Here, PCDH9 is linked to Miyoshi myopathy.